SOPHiA GENETICS (NASDAQ:SOPH) CTO Abhimanyu Verma Sells 6,944 Shares

SOPHiA GENETICS SA (NASDAQ:SOPH) CTO Abhimanyu Verma sold 6,944 shares of the stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $5.51, for a total transaction of $38,261.44. Following the sale, the chief technology officer directly owned 197,456 shares of the company’s stock, valued at $1,087,982.56. The trade was a 3.40% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Abhimanyu Verma also recently made the following trade(s):

• On Tuesday, April 7th, Abhimanyu Verma sold 1,030 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.87, for a total value of $5,016.10.
• On Monday, April 6th, Abhimanyu Verma sold 2,519 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.86, for a total value of $12,242.34.

SOPHiA GENETICS Stock Performance

Shares of SOPH stock opened at $5.75 on Friday. The company has a quick ratio of 1.90, a current ratio of 2.06 and a debt-to-equity ratio of 1.05. The stock has a fifty day moving average of $5.07 and a 200 day moving average of $4.92. The firm has a market capitalization of $482.37 million, a price-to-earnings ratio of -11.06 and a beta of 0.98. SOPHiA GENETICS SA has a 52 week low of $2.81 and a 52 week high of $5.94.

SOPHiA GENETICS (NASDAQ:SOPH) last posted its earnings results on Tuesday, May 5th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.04). SOPHiA GENETICS had a negative return on equity of 62.74% and a negative net margin of 44.48%.The company had revenue of $21.69 million during the quarter, compared to analysts’ expectations of $20.40 million.

Analysts Set New Price Targets

A number of research analysts recently issued reports on SOPH shares. BTIG Research reissued a “buy” rating and set a $8.00 price target on shares of SOPHiA GENETICS in a research report on Monday, June 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of SOPHiA GENETICS in a report on Tuesday, April 21st. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $7.50.

Institutional Investors Weigh In On SOPHiA GENETICS

Several large investors have recently bought and sold shares of the business. Royal Bank of Canada grew its stake in shares of SOPHiA GENETICS by 3,130.2% in the first quarter. Royal Bank of Canada now owns 19,381 shares of the company’s stock worth $96,000 after acquiring an additional 18,781 shares during the period. Sei Investments Co. purchased a new stake in SOPHiA GENETICS in the first quarter worth approximately $1,772,000. Principal Financial Group Inc. grew its position in SOPHiA GENETICS by 0.7% in the 1st quarter. Principal Financial Group Inc. now owns 1,409,242 shares of the company’s stock worth $6,976,000 after purchasing an additional 9,800 shares during the period. Hodges Capital Management Inc. purchased a new stake in SOPHiA GENETICS during the 1st quarter valued at $2,157,000. Finally, First Dallas Securities Inc. purchased a new stake in SOPHiA GENETICS during the 1st quarter valued at $50,000. 31.59% of the stock is currently owned by institutional investors.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.